With $135 million up front from Roche, Vividion aims to develop more potent, durable and selective targeted protein degraders by using its covalent chemistry to engage untapped ubiquitin ligases. Targeted protein degraders typically connect one...

As researchers explore next-generation CARs in cancer, one strategy is to tinker with the receptors’ modular components. A Science Signaling paper suggests that altering the number of ITAM repeats in the intracellular domains of a...

INDICATION: Renal failure; heart failure; liver failure Mouse studies suggest inhibiting YY1 or its co-repressor FKBP12 could help treat chronic renal, heart and liver failure. In a mouse model of urethral obstruction-induced chronic renal failure,...

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray published a paper in Nature Chemical Biology demonstrating a generalizable target-specific protein degradation system that can be used to create preclinical models that offer better control...

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray have demonstrated in a paper published in Nature Chemical Biology that targeted protein degradation can be used to create preclinical models that offer better control over...

Researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported preclinical data showing that prostate cancer candidate GNE-049 blocked expression of key proliferative genes and reduced tumor growth. In patient-derived xenograft mouse models of...

Preclinical evidence supporting dual inhibition of E1A binding protein p300 (EP300; p300) and CREB binding protein ( CREBBP ; CBP) as an epigenetic strategy for treating prostate cancer is mounting. In a paper published in Cancer...

The master regulator mTOR has made its mark as the target of dozens of drugs and clinical candidates for diseases ranging from cancer to diabetes, but David Sabatini thinks its full therapeutic value won’t be...

INDICATION: Inflammation Mouse studies suggest topical tacrolimus could help treat lymphedema. In a mouse tail model of lymphedema, a topical formulation of tacrolimus decreased tail swelling and volume, soft tissue thickness, infiltration of inflammatory cells...

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...